Please Wait.....
Report
Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends
Market Research Report I 2023-08-18 I 122 Pages I BCC Research
Description
Report Scope:
This report aims to comprehensively study the market size of AML and treatments for a global market. Current and historical market revenues can be estimated based on treatment type, route of administration, end use, distribution channel and region.
Report Includes:
- 42 data tables and 57 additional tables
- An overview of the global market for acute myeloid leukemia (AML) treatment
- Analyses of global market trends, with data from 2020 to 2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
- Highlights of the market potential and characterization of AML market based on treatment type, route of administration type, end-users, distribution channel, region
- Coverage of various risk factors associated with AML, such as exposure to radiation or chemicals, genetic disorders, and weakened immune system
- Description of major treatment options for AML such as, chemotherapy, targeted therapy, and stem cell transplantation
- Information on recent mergers, acquisitions, collaborations, agreements, partnerships, product launches, and expansions in the market and a relevant patent analysis
- Detailed company profiles of major players in the market of the industry, including AbbVie, Daiichi Sankyo, GlaxoSmithKline PLC, Pfizer Inc. and Servier
Executive Summary
Summary:
The global AML treatment market was valued at nearly $REDACTED billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED%, expected to reach $REDACTED billion by 2028. Growth in this market is fueled by a worldwide increase in elder populations and an increased prevalence of AML.
Technological innovation is an important catalyst driving the adaptation and use.
In 2020, AML treatment was significantly impacted by the COVID-19 pandemic, which led to the shutdown of cancer hospitals and chemotherapy procedures. The transition towards normalcy in the second half of 2021 and the resumption of elective procedures is driving sales of AML treatments.
In 2022, the targeted therapy segment held the highest market share at about REDACTED%, followed by anthracycline drugs at REDACTED% and other chemotherapies at REDACTED%
Reasons for Doing This Study:
The prevalence of Acute Myeloid Leukemia (AML) is rising among the elder population, coinciding with an overall increase in the elder population. This can be attributed to lower mortality rates and a decrease in fertility rates. Advancements in technology within the field of blood cancer are instrumental in driving growth in the AML treatment market.
The COVID-19 pandemic had significant impact on the treatment rates for AML. Lockdown measures and restricted patient access to chemotherapy treatments resulted in a decline in treatment rates during this period.
The primary objective of this study is to provide a thorough analysis of the AML treatment market, facilitating a better understanding of its dynamics, trends and the overall landscape of the market.
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Chapter 2 Summary and Highlights
Market Outlook
This Report Highlights
Chapter 3 Market Overview and Definitions
Overview
Acute Myeloid Leukemia
The Global Regulatory Structure for AML
Pricing and Reimbursement for AML
Therapies/Drugs to Treat AML
FLT3 Inhibitors
IDH Inhibitors
Apoptosis Stimulants
DNA Methylation Inhibitors
DNA Intercalators
Angiogenesis Inhibitors
DNA Synthesis Inhibitors
Chapter 4 Market Dynamics
Market Drivers
Growing Elderly Population
Increasing Incidence and Prevalence
Advancements in Molecular Diagnostics
Minimal Residual Disease (MRD) Monitoring
Gene Expression Profiling
Fusion Gene Detection
Liquid Biopsies
R&D
Regulatory Environment
Personalized Medicine
Collaborative Efforts
Patient Advocacy and Awareness
Market Opportunity
Strategic Initiative
Market Restraints
High Costs
Limited Treatment Options
Treatment-related Toxicity and Adverse Effects
Regulatory and Reimbursement Challenges
Chapter 5 Impact of COVID-19
Introduction
COVID-19 Impact on AML Treatments
Chapter 6 Market Breakdown by Region
Market Overview and Discussion
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Market Breakdown by Treatment Type
Market Overview and Discussion
Targeted Therapy
Anthracycline Drugs
Other Chemotherapies
Targeted Therapy
Anthracycline Drugs
Other Chemotherapies
Chapter 8 Market Breakdown by Route of Administration
Market Overview and Discussion
Intravenous (IV) Administration
Oral Administration
Intravenous (IV) Administration
Chapter 9 Market Breakdown by Product
FLT3 Inhibitors
Apoptosis Stimulants
Angiogenesis Inhibitors
DNA Methylation Inhibitors
DNA Synthesis Inhibitors
DNA Intercalators
Chapter 10 ESG Development
Introduction
Environment
Governance
Chapter 11 Emerging Trends and Technologies
Introduction
Chapter 12 Competitive Landscape
Overview
Industry Scenario
Company Shares
Chapter 13 Patent Analysis
Patent Analysis by Manufacturer
Chapter 14 Pipeline Analysis
Clinical Trail Scenario
Chapter 15 M&A and Venture Funding Outlook
Introduction
Chapter 16 Company Profiles
ABBVIE
AMGEN INC.
ASTELLAS PHARMA INC.
BAYER AG
BIOGEN
BRISTOL MYERS SQUIBB
DAIICHI SANKYO CO. LTD.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
MERCK & CO. INC.
NOVARTIS
PFIZER INC.
SANOFI
SERVIER LABORATORIES
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter 17 Appendix: Acronyms
List of Tables
Summary Table : Global Market for AML Treatments, by Drug Type, Through 2028
Table 1 : Global Population, Aged 60+, 2010-2050
Table 2 : North America, New Patents, 2023
Table 3 : AML Treatment: Targeted Therapy Drugs
Table 4 : AML Treatment Cost, by Country
Table 5 : AML Treatment-related Toxicities and Adverse Effects
Table 6 : Global COVID-19 Cases, 2023
Table 7 : Global Market for AML Treatments, by Region, Through 2028
Table 8 : North American Market for AML Treatments, by Country, Through 2028
Table 9 : European Market for AML Treatments, by Country, Through 2028
Table 10 : Asia-Pacific Market for AML Treatments, by Country, Through 2028
Table 11 : RoW Market for AML Treatments, Through 2028
Table 12 : Global AML, by Treatment Type, Targeted Therapy
Table 13 : Global Market for AML Treatments, by Targeted Therapy, Through 2028
Table 14 : Global Market for AML Treatments, by Anthracycline Drugs, Through 2028
Table 15 : Global Market for AML Treatments, by Other Chemotherapies, Through 2028
Table 16 : Global Market for AML Treatments, by IV Administration, Through 2028
Table 17 : Global AML IV Treatment
Table 18 : Global AML IV Treatment Cycle
Table 19 : Global Market for AML Treatments, by Oral Route Administration, Through 2028
Table 20 : Global AML, Oral Treatment
Table 21 : Global Market for AML Treatments, by Product, Through 2028
Table 22 : Global Market for AML Treatments, FLT3 Inhibitors, Through 2028
Table 23 : Global Market for AML Treatments, Apoptosis Stimulants, Through 2028
Table 24 : Global Market for AML Treatments, IDH Inhibitors, Through 2028
Table 25 : Global Market for AML Treatments, Angiogenesis Inhibitors, Through 2028
Table 26 : Global Market for AML Treatments, DNA Methylation Inhibitors, Through 2028
Table 27 : Global Market for AML Treatments, DNA Synthesis Inhibitors, Through 2028
Table 28 : Global Market for AML Treatments, DNA Intercalators, Through 2028
Table 29 : ESG Framework for the Global Pharmaceutical Industry
Table 30 : Social Framework, Global Pharmaceutical Industry
Table 31 : Top Pharma Companies, ESG Ratings
Table 32 : Global Market for AML Treatments, New Technologies
Table 33 : Global AML Treatments, by Company Market Share, 2022
Table 34 : Global AML Treatments, by Product Share, 2022
Table 35 : Global AML Treatments, by Product Sales, 2022
Table 36 : Global AML Treatments, Company Information
Table 37 : Global AML Treatments, Key Financials, 2022
Table 38 : Patents on AML Drugs, 2018-Present
Table 39 : Selected Manufacturer Patents on AML Drugs, 2018-Present
Table 40 : Patents on FLT3 Inhibitors, 2018-Present
Table 41 : Selected Manufacturer Patents on FLT3 Inhibitors, 2018-Present
Table 42 : Patents on Apoptosis Stimulants, 2018-Present
Table 43 : Selected Manufacturer Patents on Apoptosis Stimulants, 2018-Present
Table 44 : Patents on IDH Inhibitors, 2018-Present
Table 45 : Selected Manufacturer Patents on IDH Inhibitors, 2018-Present
Table 46 : Patents on Anaplastic Lymphoma Kinase Inhibitors, 2018-Present
Table 47 : Selected Manufacturer Patents on Anaplastic Lymphoma Kinase Inhibitors, 2018-Present
Table 48 : Patents on DNA Methylation Inhibitor, 2018-Present
Table 49 : Selected Manufacturer Patents on DNA Methylation Inhibitor, 2018-Present
Table 50 : Selected Apoptosis Stimulants in Clinical Trials, 2023
Table 51 : Selected IDH Inhibitors in Clinical Trials, 2023
Table 52 : Selected IDH Inhibitors in Clinical Trials, 2023
Table 53 : Selected DNA Methylation Inhibitors in Clinical Trials, 2023.
Table 54 : Selected FLT3 Inhibitors in Clinical Trials, 2023
Table 55 : Selected DNA Synthesis Inhibitors in Clinical Trials, 2023
Table 56 : Global AML Treatment Market: Mergers and Acquisitions, 2019-2022
Table 57 : AbbVie: Product Information
Table 58 : AbbVie: Revenue, 2020-2022
Table 59 : AbbVie: Recent Key Developments
Table 60 : Amgen: Revenue, 2020-2022
Table 61 : Amgen: Key Developments, 2021 and 2022
Table 62 : Astellas Pharma: Revenue, 2020-2022
Table 63 : Astellas Pharma: Recent Key Developments
Table 64 : Bayer AG: Marketed Products
Table 65 : Bayer AG: Annual Revenue, 2020-2022
Table 66 : Bayer AG: Key Developments, 2022 and 2023
Table 67 : Biogen: Annual Revenue, 2020-2022
Table 68 : Biogen: Key Developments, 2018-2023
Table 69 : Bristol-Myers Squibb: Product Information
Table 70 : Bristol-Myers Squibb: Revenue, 2020-2022
Table 71 : Bristol-Myers Squibb: Key Developments, 2020 and 2021
Table 72 : Daiichi Sankyo: Product Information
Table 73 : Daiichi Sankyo: Annual Revenue, 2020-2022
Table 74 : Daiichi Sankyo: Key Developments, 2022 and 2023
Table 75 : Gilead Sciences: Annual Revenue, 2020-2022
Table 76 : Gilead Sciences: Key Developments, 2022 and 2023
Table 77 : GlaxoSmithKline PLC: Product Segment
Table 78 : GlaxoSmithKline PLC: Annual Revenue, 2020-2022
Table 79 : GlaxoSmithKline PLC: Recent Developments, 2022
Table 80 : Merck & Co. Inc.: Business Segment
Table 81 : Merck & Co. Inc.: Annual Revenue, 2020-2022
Table 82 : Merck & Co. Inc.: Key Developments, 2022
Table 83 : Novartis: Product Information
Table 84 : Novartis: Revenue, 2020-2022
Table 85 : Novartis: Key Developments
Table 86 : Pfizer Inc.: Product Segments
Table 87 : Pfizer Inc.: Annual Revenue, 2020-2022
Table 88 : Pfizer Inc.: Top Brands, 2022
Table 89 : Pfizer Inc.: Key Developments, 2019-2023
Table 90 : Sanofi: Business Segment
Table 91 : Sanofi: Annual Revenue, 2020-2022
Table 92 : Sanofi: Key Developments, 2021-2023
Table 93 : Servier: Product Information
Table 94 : Servier: Annual Revenue, 2020-2022
Table 95 : Servier: Key Developments, 2022 and 2023
Table 96 : Teva: Financials, 2020-2022
Table 97 : Teva: Key Developments, 2021-2023
Table 98 : Acronyms Used in This Report
List of Figures
Summary Figure A : Global Market for AML Treatments, by Drug Type, 2020-2028
Summary Figure B : Global Market Shares of AML Treatments, by Drug Type, 2022
Figure 1 : Global Market Shares of AML Treatments, by Region, 2022
Figure 2 : North American Market Shares of AML Treatments, by Country, 2022
Figure 3 : European Market Shares of AML Treatments, by Country, 2022
Figure 4 : Asia-Pacific Market Shares of AML Treatments, by Country, 2022
Figure 5 : Global AML Treatment Market Shares, by Drug Type, 2022
Figure 6 : Global Market Shares of AML Treatments, by Route of Administration, 2022
Figure 7 : Global Market Shares of AML Treatments, by Oral Route Administration, 2022
Figure 8 : Global Market Shares of AML Treatments, by Product, Through 2028
Figure 9 : Global Electricity from Renewable Sources, 2017-2021
Figure 10 : Global Recycled Waste, 2017-2021
Figure 11 : Global CO2 Emissions, 2017-2021
Figure 12 : Global AML Treatments, by Company Market Share, 2022
Figure 13 : Global AML Treatments, by Product Sales, 2022
Figure 14 : AbbVie: Market Share, by Country, 2022
Figure 15 : Bristol-Myers Squibb: Revenue Share, by Country, 2022
Figure 16 : Daiichi Sankyo: Market Share, by Region/Country, 2022
Figure 17 : Gilead Sciences: Revenue, by Product, 2022
Figure 18 : GlaxoSmithKline PLC: Annual Revenue, by Segment, 2020-2022
Figure 19 : Merck & Co. Inc.: Annual Revenue, by Segment, 2020-2022
Figure 20 : Novartis Innovative Medicine: Market Share, by Region/Country, 2022
Figure 21 : Novartis Sandoz: Market Share, by Region/Country, 2022
Figure 22 : Sanofi: Revenue, by Region/Country, 2022
Figure 23 : Sanofi: Revenue, by Segment, 2022
Figure 24 : Teva: Market Share, by Region, 2022
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security